EP3209331C0 - Solution ophtalmique - Google Patents

Solution ophtalmique

Info

Publication number: EP3209331C0
Authority: EP; European Patent Office
Prior art keywords: eye solution; eye; solution
Prior art date: 2014-10-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

EP15791036.5A

Other languages

German (de)

English (en)

Other versions

EP3209331A1 (fr

EP3209331B1 (fr

Inventor

Mandar V Shah

Deepak Bahri

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sentiss Pharma Pvt Ltd

Original Assignee

Sentiss Pharma Pvt Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-20

Filing date

2015-10-16

Publication date

2023-07-12

2015-10-16 Application filed by Sentiss Pharma Pvt Ltd filed Critical Sentiss Pharma Pvt Ltd

2017-08-30 Publication of EP3209331A1 publication Critical patent/EP3209331A1/fr

2023-07-12 Application granted granted Critical

2023-07-12 Publication of EP3209331C0 publication Critical patent/EP3209331C0/fr

2023-07-12 Publication of EP3209331B1 publication Critical patent/EP3209331B1/fr

Status Active legal-status Critical Current

2035-10-16 Anticipated expiration legal-status Critical

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oil, Petroleum & Natural Gas (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

EP15791036.5A 2014-10-20 2015-10-16 Solution ophtalmique Active EP3209331B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN2985DE2014		2014-10-20
PCT/IB2015/057963 WO2016063184A1 (fr)	2014-10-20	2015-10-16	Solution ophtalmique

Publications (3)

Publication Number	Publication Date
EP3209331A1 EP3209331A1 (fr)	2017-08-30
EP3209331C0 true EP3209331C0 (fr)	2023-07-12
EP3209331B1 EP3209331B1 (fr)	2023-07-12

Family

ID=54477035

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP15791036.5A Active EP3209331B1 (fr)	2014-10-20	2015-10-16	Solution ophtalmique

Country Status (7)

Country	Link
US (1)	US11285163B2 (fr)
EP (1)	EP3209331B1 (fr)
JP (1)	JP6704400B2 (fr)
EA (1)	EA034839B1 (fr)
ES (1)	ES2954412T3 (fr)
UA (1)	UA124698C2 (fr)
WO (1)	WO2016063184A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA124698C2 (uk)	2014-10-20	2021-11-03	Сентіс Фарма Прайвет Лімітед	Офтальмологічний розчин
WO2017055454A1 (fr)	2015-09-30	2017-04-06	Novaliq Gmbh	Composés semi-fluorés et leurs compositions
US20190209465A1 (en) *	2016-07-01	2019-07-11	Pharmathen S.A.	Process for preparing pharmaceutical ophthalmic compositions of brinzolamide
JP6931493B2 (ja) *	2017-06-22	2021-09-08	ヨンスンファインケミカルカンパニー，リミテッド	緑内障治療用点眼組成物
CN110269867B (zh) *	2018-03-14	2022-06-21	必康生技（香港）有限公司	用于生物流体净化的组合物
JP7496778B2 (ja) *	2018-03-28	2024-06-07	ノバリックゲーエムベーハー	チモロールを含む医薬組成物
JP2021521240A (ja) *	2018-04-25	2021-08-26	シルパメディケアリミテッドＳｈｉｌｐａＭｅｄｉｃａｒｅＬｉｍｉｔｅｄ	ブリンゾラミドの眼科用組成物
WO2019206956A1 (fr)	2018-04-27	2019-10-31	Novaliq Gmbh	Compositions ophtalmiques comprenant du tafluprost pour le traitement du glaucome
GR1009616B (el) *	2018-07-20	2019-10-11	Φαρματεν Α.Β.Ε.Ε.	Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει βρινζολαμιδη και τιμολολη και μεθοδος παρασκευης αυτου
CA3115664A1 (fr) *	2018-08-29	2020-03-05	Ocugen, Inc.	Compositions ophtalmiques et methodes d'utilisation
MY206642A (en)	2018-10-12	2024-12-30	Novaliq Gmbh	Ophthalmic composition for treatment of dry eye disease
CN110193084A (zh) *	2019-07-02	2019-09-03	付纪军	一种含聚乙烯己内酰胺-聚乙酸乙烯酯-聚乙二醇接枝共聚物的药物制剂及其制备方法
AU2020340561A1 (en)	2019-09-06	2022-03-31	Novaliq Gmbh	Ophthalmic composition for the treatment of uveitis
IL271763A (en) *	2019-12-30	2021-06-30	Michael Belkin	Preparations, kits and methods for the treatment of glaucoma
WO2021240376A2 (fr)	2020-05-27	2021-12-02	Lupin Limited	Compositions de nanoémulsion ophtalmique
US11850249B2 (en) *	2020-10-05	2023-12-26	Somerset Therapeutics, Llc	Methods of efficiently reducing intraocular pressure
WO2022081297A1 (fr) *	2020-10-12	2022-04-21	The Regents Of The University Of Colorado, A Body Corporate	Compositions et méthodes pour abaisser la pression intracrânienne par administration intranasale d'un agent
JP6855026B1 (ja) *	2020-11-09	2021-04-07	東亜薬品株式会社	タフルプロスト点眼液
WO2024241345A1 (fr) *	2023-05-22	2024-11-28	Sentiss Pharma Private Limited	Composition de suspension ophtalmique de brinzolamide et de latanoprost
WO2025230326A1 (fr) *	2024-04-30	2025-11-06	주식회사태준제약	Composition ophtalmique comprenant de la pilocarpine

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4599353A (en)	1982-05-03	1986-07-08	The Trustees Of Columbia University In The City Of New York	Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
ATE108330T1 (de)	1987-09-18	1994-07-15	R Tech Ueno Ltd	Hypotensive okulare mittel.
ATE420857T1 (de)	1988-09-06	2009-01-15	Pfizer Health Ab	Prostaglandin-derivate zur behandlung von glaukom und ocularer hypertension
US5153192A (en)	1990-04-09	1992-10-06	Alcon Laboratories, Inc.	Thiophene sulfonamides useful as carbonic anhydrase inhibitors
US5378703A (en) *	1990-04-09	1995-01-03	Alcon Laboratories, Inc.	Sulfonamides useful as carbonic anhydrase inhibitors
US5352708A (en)	1992-09-21	1994-10-04	Allergan, Inc.	Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5510383A (en)	1993-08-03	1996-04-23	Alcon Laboratories, Inc.	Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
FR2754712B1 (fr) *	1996-10-17	1999-09-03	Merck Sharp Dohme Chibret Lab	Compositions ophtalmiques
US6071904A (en)	1996-12-11	2000-06-06	Alcon Laboratories, Inc.	Process for manufacturing ophthalmic suspensions
MX2009000885A (es)	2006-07-25	2009-02-05	Osmotica Corp	Soluciones oftalmicas.
WO2008027340A2 (fr) *	2006-08-30	2008-03-06	Merck & Co., Inc.	Formulations ophtalmiques locales
TWI544927B (zh)	2008-03-17	2016-08-11	愛爾康研究有限公司	具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
JP2010037327A (ja) *	2008-07-07	2010-02-18	Wakamoto Pharmaceut Co Ltd	ブリンゾラミド水性組成物
JP5558582B2 (ja)	2009-12-03	2014-07-23	ルピン・リミテッド	眼科用医薬組成物の調製方法
CA2805425C (fr) *	2010-07-15	2019-07-23	Corinthian Ophthalmic, Inc.	Administration de medicament ophtalmique
JP2014520895A (ja) *	2011-07-20	2014-08-25	アラーガンインコーポレイテッド	ビマトプロストおよびブリモニジンの固定用量の組み合わせ
US20130035338A1 (en) *	2011-08-05	2013-02-07	Gordon Tang	Eyelid treatment
RU2014129268A (ru) *	2011-12-16	2016-02-10	Аллерган, Инк.	Офтальмологические составы, которые содержат привитые сополимеры поливинилкапролактам-поливинилацетат-полиэтиленгликоля
GR1007906B (el) *	2012-03-22	2013-05-30	Φαρματεν Αβεε,	Οφθαλμικο φαρμακευτικο σκευασμα περιεχον ενα αναστολεα καρβονικης ανυδρασης και μεθοδος για την παρασκευη αυτου
EP3096740B1 (fr) *	2014-01-24	2020-09-30	Sentiss Pharma Private Limited	Composition pharmaceutique comprenant du brinzolamide
UA124698C2 (uk)	2014-10-20	2021-11-03	Сентіс Фарма Прайвет Лімітед	Офтальмологічний розчин

2015
- 2015-10-16 UA UAA201704818A patent/UA124698C2/uk unknown
- 2015-10-16 WO PCT/IB2015/057963 patent/WO2016063184A1/fr not_active Ceased
- 2015-10-16 US US15/520,217 patent/US11285163B2/en active Active
- 2015-10-16 EA EA201790889A patent/EA034839B1/ru not_active IP Right Cessation
- 2015-10-16 EP EP15791036.5A patent/EP3209331B1/fr active Active
- 2015-10-16 ES ES15791036T patent/ES2954412T3/es active Active
- 2015-10-16 JP JP2017540335A patent/JP6704400B2/ja active Active

Also Published As

Publication number	Publication date
EP3209331A1 (fr)	2017-08-30
EA034839B1 (ru)	2020-03-26
ES2954412T3 (es)	2023-11-22
US20170304316A1 (en)	2017-10-26
JP6704400B2 (ja)	2020-06-03
EA201790889A1 (ru)	2017-08-31
WO2016063184A1 (fr)	2016-04-28
US11285163B2 (en)	2022-03-29
EP3209331B1 (fr)	2023-07-12
JP2017531045A (ja)	2017-10-19
UA124698C2 (uk)	2021-11-03

Publication	Publication Date	Title
FIC20240015I1 (fi)	2024-05-28	Zilbrysq - tsilukoplaani
FIC20220017I1 (fi)	2022-06-03	Lonapegsomatropiini
IL249643A0 (en)	2017-02-28	Ophthalmic composition
EP3209331C0 (fr)	2023-07-12	Solution ophtalmique
DK3183051T3 (da)	2020-06-02	Væske-til-luftmembranenergivekslere
DK3134402T3 (da)	2020-07-20	4-amino-imidazoquinolinforbindelser
DK3006072T3 (da)	2021-10-25	Karadgang
DK3211743T3 (da)	2019-12-16	Ø-til-netværk-omskiftningsfremgangsmåde
DK3119396T3 (da)	2021-05-31	Muscarinreceptoragonister
FIC20230016I1 (fi)	2023-04-26	Nirsevimabi
DK3183340T3 (da)	2019-08-19	Termolabile exonukleaser
DE112015005041A5 (de)	2017-08-31	Gargerätevorrichtung
DK3110439T3 (da)	2019-05-13	Pcsk9-vacciner
DK3009858T3 (da)	2021-08-09	Skyradar
FI20145913A (fi)	2016-04-18	Staattorimekanismi
DE112015001633A5 (de)	2017-02-23	Betätigungsaktuator
DK3447493T3 (da)	2020-08-17	Proteinrettede ortologer
DE202014005655U8 (de)	2014-11-13	llluminationsvorrichtung
DE112015005055A5 (de)	2017-08-03	Gargerätevorrichtung
DK3091875T3 (da)	2019-10-14	Vipbar taburet
FI20146001A (fi)	2016-05-15	Tahnatuubin puristin
ITUB20156017A1 (it)	2017-05-30	Collirio oftalmico
DK3191825T3 (da)	2019-05-06	Kreatininbiosensor
ITVA20140029U1 (it)	2016-04-24	Astuccio bombato
FI10894U1 (fi)	2015-06-11	Putkieristyskouru

Legal Events

Date	Code	Title	Description
2017-03-07	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2017-07-28	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2017-07-28	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2017-08-30	17P	Request for examination filed	Effective date: 20170307
2017-08-30	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2017-08-30	AX	Request for extension of the european patent	Extension state: BA ME
2018-01-24	DAV	Request for validation of the european patent (deleted)
2018-01-24	DAX	Request for extension of the european patent (deleted)
2018-07-20	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2018-08-22	17Q	First examination report despatched	Effective date: 20180720
2023-01-24	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2023-01-24	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2023-02-22	INTG	Intention to grant announced	Effective date: 20230125
2023-05-31	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2023-06-09	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2023-06-09	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2023-07-12	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2023-07-14	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2023-08-02	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2023-08-03	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602015084552 Country of ref document: DE
2023-09-20	U01	Request for unitary effect filed	Effective date: 20230811
2023-09-20	U07	Unitary effect registered	Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI Effective date: 20230818
2023-11-10	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG9D
2023-11-22	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2954412 Country of ref document: ES Kind code of ref document: T3 Effective date: 20231122
2023-11-29	U20	Renewal fee for the european patent with unitary effect paid	Year of fee payment: 9 Effective date: 20231020
2024-01-18	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231013
2024-01-23	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231112
2024-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230712 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231012 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231112 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230712 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231013
2024-02-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230712
2024-04-15	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602015084552 Country of ref document: DE
2024-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230712 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230712 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230712 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230712
2024-05-17	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2024-05-17	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2024-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230712
2024-06-19	26N	No opposition filed	Effective date: 20240415
2024-10-10	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231016
2024-10-14	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20240926 Year of fee payment: 10
2024-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231016
2024-11-13	U20	Renewal fee for the european patent with unitary effect paid	Year of fee payment: 10 Effective date: 20241007
2025-01-28	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: ES Payment date: 20241108 Year of fee payment: 10
2025-01-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CH Payment date: 20241101 Year of fee payment: 10
2025-02-03	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: TR Payment date: 20241001 Year of fee payment: 10
2025-07-25	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20151016
2025-08-18	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20151016
2025-11-01	REG	Reference to a national code	Ref country code: CH Ref legal event code: U11 Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE) Effective date: 20251101
2025-11-26	U20	Renewal fee for the european patent with unitary effect paid	Year of fee payment: 11 Effective date: 20251023